Reacción a "EMA recommends not approving donanemab for Alzheimer's"

 The EMA decision is unsurprising as the benefits of treatment are extremely small and would be impossible to detect in a single patient. The risks of treatment are significant. However, it is worth bearing in mind that EMA made a similar initial decision about lecanemab last year but reversed this for a group of people with Alzheimer’s disease after the manufacturer appealed.